YH14755 + Metformin + Rosuvastatin
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia, Type II Diabetes
Trial Timeline
Nov 4, 2015 โ Jul 7, 2017
NCT ID
NCT02586129About YH14755 + Metformin + Rosuvastatin
YH14755 + Metformin + Rosuvastatin is a phase 3 stage product being developed by Yuhan for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02586129. Target conditions include Dyslipidemia, Type II Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02586129 | Phase 3 | Completed |
Competing Products
20 competing products in Dyslipidemia
Other Products from Yuhan
generic formulation of atorvastatin (Atorvaยฎ) + branded formulation of atorvastatin (Lipitorยฎ)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85